Mineralys Therapeutics price target raised to $56 from $52 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Mineralys Therapeutics (MLYS) to $56 from $52 and keeps a Buy rating on the shares. The firm is “enthusiastic” as Mineralys heads towards the near-term application submission for its oral selective aldosterone synthase inhibitor candidate lorundrostat.